Michael Yang leads list of moves at Vi­a­Cyte, suc­ceed­ing Paul Laikind as CEO; Qasim Rizvi named CEO of Take­da part­ner KSQ

→ The winds of change are fresh­en­ing off the coast in San Diego for stem cell biotech Vi­a­Cyte, which has ap­point­ed Michael Yang as pres­i­dent and CEO. Yang re­places Paul Laikind, who re­tired as Vi­a­Cyte’s CEO in Sep­tem­ber af­ter eight years at the helm, and leaves his pre­vi­ous gig as chief com­mer­cial of­fi­cer of Aca­dia Phar­ma­ceu­ti­cals ef­fec­tive to­day. Pri­or to his near­ly four years at Aca­dia, Yang was Janssen’s pres­i­dent in charge of their US im­munol­o­gy busi­ness, and be­fore that, he was the J&J sub­sidiary’s CNS pres­i­dent.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.